The Use of Hallucinogens in the Treatment of Addiction

References

• Use of LSD in Psychotherapy and Alcoholism, H. A. Abramson. Bobbs Merrill, Indianapolis, IN 1967
   Google Scholar
• Abuzzahab F. S., Anderson B. J. A Review of LSD Treatment in Alcoholism. International Pharmacopsychiatry 1971; 6: 223–235
   PubMedGoogle Scholar
• Aceto M. D., Bowman E. R., Harris L. S., May E. L. Dependence studies of new compounds in the rhesus monkey, rat and mouse. N1DA Research Monograph 1989; 95: 578–631
   PubMedGoogle Scholar
• Albaugh B. J., Anderson P. O. Peyote in the Treatment of Alcoholism Among American Indians. American Journal of Psychiatry 1974; 131(11)1247–1250
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Press, Washington, D.C. 1994
   Google Scholar
• Anonymous. Medical News. LSD: The Search For Definite Conclusions. Journal of the American Medical Association April 25, 1966; 196(4)32–33
   Google Scholar
• Brecher E. M., the Editors of Consumer Reports. Licit & Illicit Drugs: The Consumers Union Report on Narcotics, Stimulants, Depressants, Inhalants, Hallucinogens & Marijuana–including Caffeine, Nicotine and Alcohol. Little, Brown and Company, Boston, MA 1972; 335–395
   Google Scholar
• Bravo G., Grob C. Shamans, Sacraments, and Psychiatrists. Journal of Psychoactive Drugs 1989; 21(1)123–128
   PubMed Web of Science ®Google Scholar
• Cappendijk S. L. T., Dzoljic M. R. Inhibitory effects of ibogaine on cocaine self-administration in rats. European Journal of Pharmacology, TAX 1993; 261–265
   Google Scholar
• Clarke P. B., Hommer D. W., Pert A., Skirboll L. R. Electrophysiological actions of nicotine on substantia nigra single units. British Journal of Pharmacology 1985; 85(4)827–835
   PubMed Web of Science ®Google Scholar
• Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceeds of the National Academy of Sciences 1988; 85(14)5274–5278
   PubMed Web of Science ®Google Scholar
• Domino E. F. Indole Hallucinogens as Animal Models of Schizophrenia. Animal Models in Human Psychobiology. Plenum Press, New York 1976; 239–259
   Google Scholar
• Dzoljic E. D., Kaplan C. D., Dzoljic M. R. Effect of Ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine dependent rats. Archives Internationales De Pharmacodynamic Et De Therapie 1988; 294: 64–70
   PubMedGoogle Scholar
• Faillace L. A., Vourlekis A., Szara S. Clinical Evaluation of Some Hallucinogenic Tryptamine Derivatives. Journal of Nervous and Mental Disease 1967; 145(4)306–313
   PubMed Web of Science ®Google Scholar
• Faillace L., Vourlekis A., Szara S. Hallucinogenic Drugs in the Treatment of Alcoholism: A Two-year Follow-up. Comprehensive Psychiatry 1970; 11(1)51–56
   PubMed Web of Science ®Google Scholar
• Gillin J. C., Cannon E., Magyar R., Schwartz M., Wyatt R. J. Failure of N,N-Dimethyltryptamine to evoke tolerance in cats. Biological Psychiatry 1973; 7: 213–220
   PubMed Web of Science ®Google Scholar
• Glennon R. A. Do classical hallucinogens act as 5-HT2 agonists or antagonists?. Neuropsychopharmacology 1990; 3(5–6)509–517
   PubMed Web of Science ®Google Scholar
• Glick S. D., Rossman K., Steindorf S., Maisonneuve I. M., Carlson J. N. Effects and Aftereffects of Ibogaine on Morphine Self-Administration in Rats. European Journal of Pharmacology 1991; 195: 341–345
   PubMed Web of Science ®Google Scholar
• Glick S. D., Rossman S., Rao N. C., Maisonneuve J. M., Carlson J. N. Effects of Ibogaine on Acute Signs of Morphine Withdrawal in Rats: Independence From Tremor. Neuropharmacology 1992; 31(5)497–500
   PubMed Web of Science ®Google Scholar
• Grinspoon L., Bakalar J. B. Psychedelic Drugs Reconsidered. Basic Books, New York 1979; 221–223
   Google Scholar
• Grinspoon L., Bakalar J. B. Can Drugs Be Used to Enhance the Psychotherapeutic Process?. American Journal of Psychotherapy 1986; XL(3)393–404
   Google Scholar
• Grob C. S. Psychiatric Research with Hallucinogens: What Have We Learned?. Yearbook of Ethnomedicine 1994; 3: 91–112
   Google Scholar
• Grof S. The Use of LSD in Psychotherapy. Journal of Psychedelic Drugs 1970; 3(1)52–62
   Web of Science ®Google Scholar
• Grof S., Soskin R. A., Richards W. A., Kurland A. A. DPT as an Adjunct in Psychotherapy of Alcoholics. International Pharmacopsychiatry 1973; 8: 104–115
   PubMedGoogle Scholar
• Grof S., Goodman L. E., Richards W. A., Kurland A. A. LSD-Assisted Psychotherapy in Patients with Terminal Cancer. International Pharmacopsychiatry 1973; 8: 129–144
   PubMedGoogle Scholar
• Grof S. LSD Psychotherapy, 2nd Ed. Hunter House, Alameda, CA 1994
   Google Scholar
• Heikkila R. E., Orlansky H., Cohen G. Studies on the distinction between uptake inhibition and release of 3H-dopamine in rat brain tissue slices. Biochemical Pharmacology 1975; 24(8)847–852
   PubMed Web of Science ®Google Scholar
• Hollister L. E., Shelton J., Krieger G. A Controlled Comparison of Lysergic Acid Diethylamide (LSD) and Dextroamphetamine in Alcoholics. American Journal of Psychiatry 1969; 125(10)58–63
   Web of Science ®Google Scholar
• Jensen S. E. Treatment program for alcoholics in a mental hospital. Quarterly Journal of Studies on Alcohol 1962; 23: 315–320
   PubMedGoogle Scholar
• Jensen S. E., Ramsey R. Treatment of chronic alcoholism with lysergic acid diethylamide. Canadian Psychiatric Association Journal 1963; 8: 182–188
   PubMedGoogle Scholar
• Johnson F. G. LSD in the treatment of alcoholism. American Journal of Psychiatry 1969; 126: 481–487
   PubMed Web of Science ®Google Scholar
• Kantor S. Drugs and Drinks (Letter to the Editor). American Journal of Psychiatry 1970; 126: 140
   Google Scholar
• Kosten T. A., Kosten T. R. Pharmacological Blocking Agents for Treating Substance Abuse. Journal of Nervous and Mental Disease 1991; 179(10)583–592
   PubMed Web of Science ®Google Scholar
• Kosten T. R. Neurobiology of Abused Drugs: Opioids and stimulants. Journal of Nervous and Mental Disease 1990; 178(4)217–227
   PubMed Web of Science ®Google Scholar
• Kovacic B., Domino E. F. Tolerance to behavioral effects of dimethyltryptamine (DMT) in the rat. Federation Proceedings 1974; 33: 549
   Google Scholar
• Kranzler H. R., Orrok B. The pharmacotherapy of alcoholism. Review of Psychiatry, A. Tasman, R. E. Hales, A. J. Frances. American Psychiatric Press, Washington, DC 1989; volume 8: 359–379
   Google Scholar
• Krebs K. M., Geyer M. A. Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology 1994; 113(3–4)429–437
   PubMed Web of Science ®Google Scholar
• Kurland A. A., Unger S., Shaffer J. W., Savage C. Psychedelic Therapy Utilizing LSD in the Treatment of the Alcoholic Patient: A Preliminary Report. American Journal of Psychiatry 1967; 123: 1202–1209
   PubMed Web of Science ®Google Scholar
• Kurland A. A., Savage C., Pahnke W. N., Grof S., Olsson J. E. LSD in the treatment of alcoholics. Pharmakopsychiatrie und Neuro-Psychopharmakologie 1971; 4(2)83–94
   Google Scholar
• La Barre W. The Peyole Cult. Shoe String Press, Hamden, CT 1970
   Google Scholar
• Lotsof H. S. Rapid Method for Interrupting the Narcotic Addiction Syndrome. U.S. Patent $4,499,096, 1985
   Google Scholar
• Lotsof H. S. Rapid Method for Interrupting the Cocaine and Amphetamine Abuse Syndrome. U.S. Patent $ 4,587,243, 1986
   Google Scholar
• Lotsof H. S. Rapid Method for Attenuating the Alcohol Dependency Syndrome. U.S. Patent $ 4,857,523, 1989
   Google Scholar
• Lotsof H. S. Rapid Method for Interrupting or Attenuating the Nicotine/Tobacco Dependency Syndrome. U.S. Patent $ 5.026.697, 1991
   Google Scholar
• Lotsof H. S. Ibogaine in the treatment of chemical dependence disorders: clinical perspectives. MAPS Bulletin 1995; v(3)16–27
   Google Scholar
• Ludwig A. M., Levine J. A Controlled Comparison of Five Brief Treatment Techniques Employing LSD, Hypnosis, and Psychotherapy. American Journal of Psychotherapy 1965; 417–435
   PubMed Web of Science ®Google Scholar
• Ludwig A., Levine J., Stark L., Lazar R. A Clinical Study of LSD Treatment in Alcoholism. American Journal of Psychiatry 1969; 126: 59–69
   PubMed Web of Science ®Google Scholar
• Ludwig A. M. Dr Ludwig Replies (Response). American Journal of Psychiatry 1970; 126: 140–141
   Google Scholar
• Mac-Lean J. R., MacDonald D. C., Ogden F., Wilby E. LSD-25 and mescaline as therapeutic adjuvants. Use of LSD in Psychotherapy and Alcoholism, H A. Abramson. Bobbs Merrill, Indianapolis, IN 1967; 407–426
   Google Scholar
• Maisonneuve I. M., Keller R. W., Glick S. D. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. European Journal of Pharmacology 1991; 199: 35–42
   PubMed Web of Science ®Google Scholar
• Maisonneuve 1. M., Rossman K. L., Keller R. W., Glick S. D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Research 1992; 575: 69–73
   PubMed Web of Science ®Google Scholar
• Maisonneuve I. M., Keller R. W., Glick S. D. Interactions of ibogaine and D-amphetamine: in vivo microdialysis and motor behavior in rats. Brain Research 1992; 579: 87–92
   PubMed Web of Science ®Google Scholar
• Mathews R. T., German D. C. Electrophysiological evidence for excitation of rat ventral tegmental area dopaminergic neurons by morphine. Neuroscience 1984; 11(3)617–625
   PubMed Web of Science ®Google Scholar
• Meert T., Clincke G. Evidence for a possible role of the 5-HT2 antagonist ritanserin in drug abuse. Annals of the New York Academy of Sciences 1992; 654: 483–6
   PubMed Web of Science ®Google Scholar
• Mereu G., Gadda G., Gessa G. L. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Research 1984; 292(1)63–69
   PubMed Web of Science ®Google Scholar
• Meyer R. E. Prospects for a rational pharmacotherapy of alcoholism. Journal of Clinical Psychiatry 1989; 50(11)403–412
   PubMed Web of Science ®Google Scholar
• Moghaddam B., Bunney B. S. Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: comparison to amphetamine. Synapse 1989; 4(2)156–161
   PubMed Web of Science ®Google Scholar
• Moos R. H., Moss B. S. Stay in Residential Facilities and Mental Health Care as Predictors of Readmission for Patients with Substance Use Disorders. Psychiatric Services 1995; 46(1)66–72
   PubMed Web of Science ®Google Scholar
• Mottin J. L. Drug-Induced Attenuation of Alcohol Consumption: A Review and Evaluation of Claimed, Potential or Current Therapies. Quarterly Journal of Studies on Alcohol 1973; 444–472
   PubMedGoogle Scholar
• Naranjo C. A., Sellers E. M., Lawin M. O. Modulation of ethanol intake by serotonin inhibitors. Journal of Clinical Psychiatry 1986; 47: 16–22, suppl
   PubMed Web of Science ®Google Scholar
• Naranjo C. A., Sellers E. M., Sullivan J. T., Woodley D. V., Kadlec K., Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clinical Pharmacology and Therapeutics 1987; 41: 266–274
   PubMed Web of Science ®Google Scholar
• Naranjo C. A., Sullivan J. T., Kadlec K. C., Woodley-Remus D. V., Kennedy G., Sellers E. M. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clinical Pharmacology and Therapeutics 1989; 46(3)301–309
   PubMed Web of Science ®Google Scholar
• Naranjo C. A., Poulos C. X., Bremner K. E., Lanctot K. C. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clinical Pharmacology and Therapeutics 1992; 51(6)729–739
   PubMed Web of Science ®Google Scholar
• Neill J. R. “More Than Medical Significance”: LSD and American Psychiatry 1953 to 1966. Journal of Psychoactive Drugs, 19(1)39–45
   PubMed Web of Science ®Google Scholar
• O'Hearn E., Molliver M. E. Degeneration of Purkinje Cells in Parasagittal Zones of the Cerebellar Vermis After Treatment with Ibogaine or Harmaline. Neuroscience 1993; 55(2)303–310
   PubMed Web of Science ®Google Scholar
• Osmond H., Cheek F., Albahary R., Sarett M. Some Problems in the use of LSD25 in the treatment of alcoholism. Use of LSD in Psychotherapy and Alcoholism, H A. Abramson. Bobbs Merrill, Indianapolis, IN 1967; 434–453
   Google Scholar
• Pahnke W. N., Kurland A. A., Unger S., Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. Journal of the American Medical Association 1970; 212: 1856–1863
   PubMed Web of Science ®Google Scholar
• Pahnke W. N., Kurland A. A., Unger S., Savage C, Wolf S., Goodman L. E. Psychedelic Therapy (Utilizing LSD) with Cancer Patients. Journal of Psychedelic Drugs 1970; 3(1)63–75
   Web of Science ®Google Scholar
• Parker E. M., Cubeddu L. X. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. II. Release in the presence of vesicular transmitter stores. Journal of Pharmacology and Experimental Therapeutics 1986; 237(1)193–203
   PubMed Web of Science ®Google Scholar
• Richards W. A., Rhead J. C., DiLeo F. B., Yensen R., Kurland A. A. The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients. Journal of Psychedelic Drugs 1977; 9(1)1–10
   Web of Science ®Google Scholar
• Rosenberg D. E., Isbell H., Miner E. J. Comparison of a Placebo, N-dimethyltryptamine, and 6-hy- droxy-N-dimethyltryptamine in Man. Psychopharmacologia 1963; 4: 39–42
   PubMedGoogle Scholar
• Rosenberg D. E., Isbell H., Miner E. J., Logan C. R. The Effect of N,N-Dimethyltryptamine in Human Subjects Tolerant to Lysergic Acid Diethylamide. Psychopharmacologia 1964; 5: 217–227
   PubMedGoogle Scholar
• Roy C, Choudhuri A., Irvine D. The prevalence of mental disorders among Saskatchewan Indians. Journal of Cross-Cultural Psychology 1970; 1: 383–392
   Web of Science ®Google Scholar
• Roy C. Indian Peyotists and Alcohol. American Journal of Psychiatry 1973; 130(10)329–330
   PubMedGoogle Scholar
• Salzman C. A. Controlled Therapy Research with Psychedelic Drugs: A Critique. Psychedelic Drugs, R. E. Hicks, P. J. Fink, V. B. O. Hammett. Grune & Stratton, New York, NY 1969
   Google Scholar
• Savage C, McCabe O. L. Residential Psychedelic (LSD) Therapy for the Narcotic Addict. Archives of General Psychiatry 1973; 28: 808–814
   PubMed Web of Science ®Google Scholar
• Szara S., Hearst E., Putney F. Metabolism and Behavioural Action of Psychotropic Tryptamine Homologues. International Journal of Neuropharmacology 1962; 1: 111–117
   Google Scholar
• Schultes R. E., Hofmann A. Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers. Healing Arts Press, Rochester, VT 1992
   Google Scholar
• Sershen H., Hashim A., Harsing L., Lajtha A. Ibogaine Antagonizes Cocaine-Induced Locomotor Stimulation in Mice. Life Sciences 1992; 50: 1079–1086
   PubMed Web of Science ®Google Scholar
• Sershen H., Hashim A., Lajtha A. Ibogaine Reduces Preference for Cocaine Consumption in C57BL/6By Mice. Pharmacology Biochemistry and Behavior 1993; 47: 13–19
   Web of Science ®Google Scholar
• Shagass C, Bittle R. M. Therapeutic Effects of LSD: A Follow-Up Study. Journal of Nervous and Mental Disease 1967; 144(6)471–478
   PubMed Web of Science ®Google Scholar
• Sheppard S. G. A Preliminary Investigation of Ibogaine: Case Reports and Recommendations for Further Study. Journal of Substance Abuse Treatment 1994; 11(4)379–385
   PubMed Web of Science ®Google Scholar
• Sloviter R. S., Drust E. G., Damiano B. P., Connor J. D. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats. Journal of Pharmacology and Experimental Therapeutics 1980; 214(2)231–238
   PubMed Web of Science ®Google Scholar
• Smart R. G., Storm T. The Efficacy of LSD in the Treatment of Alcoholism. Quarterly Journal of Studies on Alcohol 1964; 25: 333–338
   PubMedGoogle Scholar
• Smart R. G., Storm T, Baker E. F., Solursh L. Controlled study of lysergide in the treatment of alcoholism. I. Effects on drinking behavior. Quarterly Journal of Studies on Alcohol 1966; 27(3)469–482
   PubMedGoogle Scholar
• Smart R. G., Storm T, Baker E. E., Solursh L. Lysergic Acid Diethylamide (LSD) in the Treatment of Alcoholism: An Investigation of its Effects on Drinking Behavior, Personality Structure, and Social Functioning. University of Toronto Press, Toronto 1967
   Google Scholar
• Soskin R. A. The Use of LSD in Time-Limited Psychotherapy. Journal of Nervous and Mental Disease 1973; 157(6)410–419
   PubMed Web of Science ®Google Scholar
• Strassman R. J. Adverse Reactions to Psychedelic Drugs: A Review of the Literature. Journal of Nervous and Mental Disease 1984; 172(11)577–595
   PubMedGoogle Scholar
• Strassman R. J. Human Hallucinogenic Drug Research in the United States: A Present-day Case History and Review of the Process. Journal of Psychoactive Drugs 1991; 23(1)29–38
   PubMed Web of Science ®Google Scholar
• Strassman R. J., Quails C. R. Dose-Response Study of N,N-Dimethyltryptamine in Humans. I. Neuroendocrine, Autonomic, and Cardiovascular Effects. Archives of General Psychiatry 1994; 51: 85–97
   PubMed Web of Science ®Google Scholar
• Strassman R. J., Quails C. R., Uhlenhuth E. H., Kellner R. Dose-Response Study of N,N-Dimethyltryptamine in Humans. II. Subjective Effects and Preliminary Results of a New Rating Scale. Archives of General Psychiatry 1994; 51: 98–108
   PubMed Web of Science ®Google Scholar
• Strassman R. J. Hallucinogenic Drugs in Psychiatric Research and Treatment: Perspectives and Prospects. Journal of Nervous and Mental Disease 1995; 183(3)127–138
   PubMed Web of Science ®Google Scholar
• Ulrich R. F., Patten B. M. The Rise, Decline, and Fall of LSD. Perspectives in Biology and Medicine 1991; 34(4)561–578
   PubMed Web of Science ®Google Scholar
• Van Dusen W., Wilson W., Miners W., Hook H. Treatment of alcoholism with lysergide. Quarterly Journal of Studies on Alcohol 1967; 28(2)295–304
   PubMedGoogle Scholar
• Wang Y, Joharchi N., Fletcher P. J., Sellers E. M., Higgins G. A. Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration. Psychopharmacology 1995; 120: 134–141
   PubMed Web of Science ®Google Scholar
• Winter J. C. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. Journal of Pharmacology and Experimental Therapeutics 1978; 204(2)416–423
   PubMed Web of Science ®Google Scholar
• Winter J. C., Rabin R. A. Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacology Biochemistry and Behavior 1988; 30(3)617–624
   PubMed Web of Science ®Google Scholar
• Wise R. A., Bozarth M. A. Action of Drugs of Abuse on Brain Reward System: An Update with Specific-Attention to Opiates. Pharmacology Biochemistry and Behavior 1982; 17(2)239–243
   PubMed Web of Science ®Google Scholar